Friedrich-Carl von Rundstedt1, Douglas A Mata2, Susan Groshen3, John P Stein4, Donald G Skinner4, Walter M Stadler5, Richard J Cote6,7, Oleksandr N Kryvenko6,8, Guilherme Godoy1, Seth P Lerner1. 1. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. 2. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3. USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 4. Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 5. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA. 6. Department of Pathology, Miller School of Medicine, University of Miami, Miami, FL, USA. 7. Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, USA. 8. Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Abstract
OBJECTIVES: To investigate the association between lymphovascular invasion (LVI) and clinical outcome in organ-confined, node-negative urothelial cancer of the bladder (UCB) in a post hoc analysis of a prospective clinical trial. To explore the effect of adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) on outcome in the subset of patients whose tumours exhibited LVI. PATIENTS AND METHODS: Surgical and tumour factors were extracted from the operative and pathology reports of 499 patients who had undergone radical cystectomy (RC) for pT1-T2 N0 UCB in the p53-MVAC trial (Southwest Oncology Group 4B951/NCT00005047). The presence or absence of LVI was determined by pathological examination of transurethral resection or RC specimens. Variables were examined in univariate and multivariate Cox proportional hazards models for associations with time to recurrence (TTR) and overall survival (OS). RESULTS: Among 499 patients with a median follow-up of 4.9 years, a subset of 102 (20%) had LVI-positive tumours. Of these, 34 patients had pT1 and 68 had pT2 disease. LVI was significantly associated with TTR with a hazard ratio (HR) of 1.78 [95% confidence interval (CI) 1.15-2.77; number of events (EV) 95; P = 0.01) and with OS with a HR of 2.02 (95% CI 1.31-3.11; EV 98; P = 0.001) after adjustment for pathological stage. Among 27 patients with LVI-positive tumours who were randomised to receive adjuvant chemotherapy, receiving MVAC was not significantly associated with TTR (HR 0.70, 95% CI 0.16-3.17; EV 7; P = 0.65) or with OS (HR 0.45, 95% CI 0.11-1.83; EV 9; P = 0.26). CONCLUSIONS: Our post hoc analysis of the p53-MVAC trial revealed an association between LVI and shorter TTR and OS in patients with pT1-T2N0 disease. The analysis did not show a statistically significant benefit of adjuvant MVAC chemotherapy in patients with LVI, although a possible benefit was not excluded.
RCT Entities:
OBJECTIVES: To investigate the association between lymphovascular invasion (LVI) and clinical outcome in organ-confined, node-negative urothelial cancer of the bladder (UCB) in a post hoc analysis of a prospective clinical trial. To explore the effect of adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) on outcome in the subset of patients whose tumours exhibited LVI. PATIENTS AND METHODS: Surgical and tumour factors were extracted from the operative and pathology reports of 499 patients who had undergone radical cystectomy (RC) for pT1-T2 N0 UCB in the p53-MVAC trial (Southwest Oncology Group 4B951/NCT00005047). The presence or absence of LVI was determined by pathological examination of transurethral resection or RC specimens. Variables were examined in univariate and multivariate Cox proportional hazards models for associations with time to recurrence (TTR) and overall survival (OS). RESULTS: Among 499 patients with a median follow-up of 4.9 years, a subset of 102 (20%) had LVI-positive tumours. Of these, 34 patients had pT1 and 68 had pT2 disease. LVI was significantly associated with TTR with a hazard ratio (HR) of 1.78 [95% confidence interval (CI) 1.15-2.77; number of events (EV) 95; P = 0.01) and with OS with a HR of 2.02 (95% CI 1.31-3.11; EV 98; P = 0.001) after adjustment for pathological stage. Among 27 patients with LVI-positive tumours who were randomised to receive adjuvant chemotherapy, receiving MVAC was not significantly associated with TTR (HR 0.70, 95% CI 0.16-3.17; EV 7; P = 0.65) or with OS (HR 0.45, 95% CI 0.11-1.83; EV 9; P = 0.26). CONCLUSIONS: Our post hoc analysis of the p53-MVAC trial revealed an association between LVI and shorter TTR and OS in patients with pT1-T2N0 disease. The analysis did not show a statistically significant benefit of adjuvant MVAC chemotherapy in patients with LVI, although a possible benefit was not excluded.
Authors: Yair Lotan; Amit Gupta; Shahrokh F Shariat; Ganesh S Palapattu; Amnon Vazina; Pierre I Karakiewicz; Patrick J Bastian; Craig G Rogers; Gilad Amiel; Paul Perotte; Mark P Schoenberg; Seth P Lerner; Arthur I Sagalowsky Journal: J Clin Oncol Date: 2005-08-22 Impact factor: 44.544
Authors: Walter M Stadler; Seth P Lerner; Susan Groshen; John P Stein; Shan-Rong Shi; Derek Raghavan; David Esrig; Gary Steinberg; David Wood; Laurence Klotz; Craig Hall; Donald G Skinner; Richard J Cote Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Lakshmi P Kunju; Li You; Yingxi Zhang; Stephanie Daignault; James E Montie; Cheryl T Lee Journal: J Urol Date: 2008-09-17 Impact factor: 7.450
Authors: Luis A Kluth; Malte Rieken; Evanguelos Xylinas; Matthew Kent; Michael Rink; Morgan Rouprêt; Nasim Sharifi; Asha Jamzadeh; Wassim Kassouf; Dharam Kaushik; Stephen A Boorjian; Florian Roghmann; Joachim Noldus; Alexandra Masson-Lecomte; Dimitri Vordos; Masaomi Ikeda; Kazumasa Matsumoto; Masayuki Hagiwara; Eiji Kikuchi; Yves Fradet; Jonathan Izawa; Ricardo Rendon; Adrian Fairey; Yair Lotan; Alexander Bachmann; Marc Zerbib; Margit Fisch; Douglas S Scherr; Andrew Vickers; Shahrokh F Shariat Journal: Eur Urol Date: 2013-12-05 Impact factor: 20.096
Authors: Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes Journal: Eur Urol Date: 2011-03-23 Impact factor: 20.096
Authors: Shahrokh F Shariat; Robert S Svatek; Derya Tilki; Eila Skinner; Pierre I Karakiewicz; Umberto Capitanio; Patrick J Bastian; Bjoern G Volkmer; Wassim Kassouf; Giacomo Novara; Hans-Martin Fritsche; Jonathan I Izawa; Vincenzo Ficarra; Seth P Lerner; Arthur I Sagalowsky; Mark P Schoenberg; Ashish M Kamat; Colin P Dinney; Yair Lotan; Michael J Marberger; Yves Fradet Journal: BJU Int Date: 2010-02-02 Impact factor: 5.588
Authors: C J Logothetis; D E Johnson; C Chong; F H Dexeus; A Sella; S Ogden; T Smith; D A Swanson; R J Babaian; K I Wishnow Journal: J Clin Oncol Date: 1988-10 Impact factor: 44.544
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Derya Tilki; Shahrokh F Shariat; Yair Lotan; Michael Rink; Pierre I Karakiewicz; Mark P Schoenberg; Seth P Lerner; Guru Sonpavde; Arthur I Sagalowsky; Amit Gupta Journal: BJU Int Date: 2012-11-26 Impact factor: 5.588
Authors: Douglas A Mata; Susan Groshen; Friedrich-Carl Von Rundstedt; Donald G Skinner; Walter M Stadler; Richard J Cote; John P Stein; Seth P Lerner Journal: J Surg Oncol Date: 2015-04-14 Impact factor: 3.454
Authors: E Compérat; J R Srigley; F Brimo; B Delahunt; M Koch; A Lopez-Beltran; V Reuter; H Samaratunga; J H Shanks; T Tsuzuki; T van der Kwast; M Varma; F Webster; D Grignon Journal: Virchows Arch Date: 2020-01-08 Impact factor: 4.064
Authors: Peter J Boström; Tuomas Mirtti; Bas van Rhijn; Neil E Fleshner; Antonio Finelli; Matti Laato; Michael A Jewett; Malcom J Moore; Srikala Sridhar; Martti Nurmi; Ian F Tannock; Alexandre R Zlotta Journal: Bladder Cancer Date: 2016-04-27